EMVision Secures AU$12 million to Advance Stroke Diagnosis Technology

EMVision Medical Devices Ltd (ASX: EMV) has successfully raised AU$12 million through a placement supported by institutional and sophisticated investors, with strategic shareholder Keysight Technologies participating pro-rata. The funds will drive progress across its emu™ in-hospital device and First Responder pre-hospital program through FY26 and FY27, covering FDA submissions, clinical trials, and commercialisation efforts.

EMVision has also opened a Share Purchase Plan, giving eligible shareholders the chance to invest up to AU$1 million in total, with the option to accept oversubscriptions of up to AU$2 million. The placement issued new shares at AU$1.94 each, a discount to recent market prices, alongside free attaching options. Headquartered in Sydney and Brisbane, EMVision develops portable and affordable neurodiagnostic devices designed to provide fast and safe stroke and acute care diagnosis at the patient’s bedside.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com